Publications

1. Package advice brexucabtagene autoleucel (Tecartus®) refractory mantle cell lymphoma

   The National Health Care Institute advises the Minister not to include brexucabtagene autoleucel (Tecartus®) in the basic health ...

   Report | 09-09-2022

2. Package advice sacituzumab govitecan (Trodelvy®) for the treatment of inoperable or metastasized triple-negative breast cancer

   The National Health Care Institute advises the Minister to include sacituzumab govitecan (Trodelvy®) in the basic health care ...

   Report | 29-07-2022

3. GVS advice testosterone undecanoate (Nebido®)

   The National Health Care Institute advises the Minister to include finerenon (Kerendia®) in List 1B of the GVS. Finerenon is ...

   Report | 21-07-2022

4. Package advice risdiplam (Evrysdi®) for the treatment of 5q spinal muscular atrophy (SMA)

   The National Health Care Institute advises the Minister to include risdiplam (Evrysdi®) in the health insurance package for the ...

   Report | 15-07-2022

5. GVS advice setmelanotide (Imcivree®)

   The National Health Care Institute advises the Minister to include setmelanotide (Imcivree®) in List 1B of the GVS. Setmelanotide ...

   Report | 08-07-2022

6. GVS advice metreleptin (Myalepta®)

   The National Health Care Institute advises the Minister to include metreleptin (Myalepta®) in List 1B of the GVS. Metreleptin is ...

   Report | 08-07-2022

7. GVS advice bempedoic acid (Nilemdo®) for use in adults with primary hypercholesterolaemia or mixed dyslipidaemia

   The National Health Care Institute has completed its assessment whether bempedoic acid is interchangeable with another medicinal ...

   Report | 05-07-2022

8. GVS advice cannabidiol (Epidyolex®) as adjuvant treatment for 2 epileptic disorders

   The National Health Care Institute advises the Minister only to include cannabidiol (Epidyolex®) on List 1B of the Medicine ...

   Report | 04-07-2022

9. Position of the National Health Care Institute on nivolumab (Opdivo®) for the treatment of dMMR- of MSI tumors

   The National Health Care Institute concludes that nivolumab (Opdivo®) for the treatment of certain patients with locally advanced ...

   Report | 23-06-2022

10. GVS advice elexacaftor/tezacaftor/ivacaftor (Kaftrio®) in combination with ivacaftor (Kalydeco®): extension of further conditions

    The National Health Care Institute advises the Minister to include cenobamate (Ontozry®) in List 1A of the GVS. Cenobamate is ...

    Report | 20-06-2022